Transplanting gut bacteria from lean, metabolically healthy donors into patients with type 2 diabetes produced a sustained and clinically meaningful improvement in insulin sensitivity, according to a randomized controlled trial published in Cell Metabolism by researchers at Amsterdam UMC.

The Gut-Metabolism Axis

A growing body of evidence implicates gut microbiome dysbiosis — an imbalance in the gut bacterial community — in the pathogenesis of insulin resistance and type 2 diabetes (T2D). Individuals with T2D consistently demonstrate reduced microbial diversity, depleted populations of butyrate-producing bacteria (particularly Akkermansia muciniphila and Faecalibacterium prausnitzii), and elevated levels of lipopolysaccharide-producing gram-negative bacteria associated with systemic inflammation.

Trial Design

The DIABEFAT trial enrolled 74 patients aged 40–70 with T2D diagnosed within the previous 10 years, HbA1c between 7–10%, and BMI 28–40. Participants were randomized to receive either autologous FMT (their own bacteria — a placebo control) or allogenic FMT from carefully screened lean donors, administered via duodenal infusion at baseline, 6 weeks, and 12 weeks.

Results

  • Peripheral insulin sensitivity (M-value on hyperinsulinemic-euglycemic clamp) improved by 44% in the FMT group vs. 8% in controls at 12 weeks (p<0.001)
  • HbA1c declined by a mean of 0.9 percentage points in FMT vs. 0.2 in controls
  • 16S rRNA sequencing confirmed durable engraftment of donor microbiota at 12-month follow-up in 68% of FMT recipients
  • Patients with highest engraftment showed greatest metabolic improvements

“We’ve shown you can transplant metabolic health. The microbiome is no longer a bystander in diabetes — it’s an active therapeutic target.”

— Dr. Max Nieuwdorp, Amsterdam UMC, lead investigator

What’s Actually Happening

Mechanistic studies embedded in the trial found that improvements in insulin sensitivity correlated with increased fecal short-chain fatty acid (SCFA) production — particularly butyrate and propionate — and reduced circulating lipopolysaccharide (LPS) levels, a marker of gut barrier disruption and systemic inflammation. These findings point toward multiple intersecting pathways through which microbiome restoration improves metabolic function.

Looking Ahead

The results pave the way for larger Phase 3 trials, and several biotechnology companies are racing to develop standardized oral microbiome therapeutics — capsulized freeze-dried bacterial preparations — that could deliver similar benefits more scalably than FMT infusions. Researchers also note that identifying which specific bacterial consortia drive the benefit could enable targeted probiotic formulations.

FMT is currently FDA-approved for recurrent C. difficile infection. Its use for metabolic disorders remains investigational in the United States.

⚕️ Medical Disclaimer: This article is for informational purposes only. It does not constitute medical advice. Always consult a qualified healthcare professional before making health decisions.